Functional Implications of MicroRNA-215 in TGF-β1-induced Phenotypic Transition of Mesangial Cells by Targeting CTNNBIP1
Overview
Affiliations
Mesangial cell (MC) phenotypic transition is crucial for the progression of diabetic nephropathy. A major stimulus mediating high glucose-induced MC phenotypic transition is TGF-β1. Our current study focuses on microRNA-215 (miR-215) and investigates its role in TGF-β1-mediated MC phenotypic transition. Using real-time quantitative PCR (qRT-PCR) and northern blotting, we determined that the miR-192/215 family is dramatically upregulated under diabetic conditions both in vitro and in vivo. Gain- and loss-of-function approaches demonstrated that miR-215 inhibition significantly inhibited TGF-β1-induced mouse mesangial cell (MMC) phenotypic transition, whereas miR-215 upregulation promoted MMC phenotypic transition. Interestingly, these changes were not detected in cells that were treated with TGF-β1 and miR-192 mimics or inhibitors. These results suggest that miR-215 participates in TGF-β1-induced MMC phenotypic transition. Luciferase reporter assays were used to identify whether catenin-beta interacting protein 1 (CTNNBIP1) is a direct target of miR-215, which was predicted by bioinformatic analysis. Mechanistic studies revealed that CTNNBIP1 suppresses Wnt/β-catenin signaling and that miR-215 promotes β-catenin activation and upregulates α-SMA and fibronectin expression in TGF-β1-treated MMCs by targeting CTNNBIP1. In addition, in vivo miR-215 silencing with a specific antagomir significantly increased CTNNBIP1 protein expression, resulting in reduced β-catenin activity and decreased α-SMA and fibronectin expression in db/db mouse kidney glomeruli. Taken together, our findings indicate that miR-215 plays an essential role in MC phenotypic transition by regulating the CTNNBIP1/β-catenin pathway, which is related to the pathogenesis of diabetic nephropathy.
Incretin-based therapy: a new horizon in diabetes management.
Zarei M, Sahebi Vaighan N, Farjoo M, Talebi S, Zarei M J Diabetes Metab Disord. 2024; 23(2):1665-1686.
PMID: 39610543 PMC: 11599551. DOI: 10.1007/s40200-024-01479-3.
Roles of microRNA-192 in diabetic nephropathy: the clinical applications and mechanisms of action.
Wan X, Liao J, Lai H, Zhang S, Cui J, Chen C Front Endocrinol (Lausanne). 2023; 14:1179161.
PMID: 37396169 PMC: 10309560. DOI: 10.3389/fendo.2023.1179161.
The Role of MicroRNA in the Pathogenesis of Diabetic Nephropathy.
Szostak J, Goracy A, Durys D, Dec P, Modrzejewski A, Pawlik A Int J Mol Sci. 2023; 24(7).
PMID: 37047185 PMC: 10094215. DOI: 10.3390/ijms24076214.
Molecular profiling of urinary extracellular vesicles in chronic kidney disease and renal fibrosis.
Tepus M, Tonoli E, Verderio E Front Pharmacol. 2023; 13:1041327.
PMID: 36712680 PMC: 9877239. DOI: 10.3389/fphar.2022.1041327.
Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease.
Yan Z, Wang G, Shi X Front Pharmacol. 2022; 12:785375.
PMID: 34992536 PMC: 8724575. DOI: 10.3389/fphar.2021.785375.